Publicité
La bourse est fermée
  • CAC 40

    8 022,41
    -0,85 (-0,01 %)
     
  • Euro Stoxx 50

    4 918,09
    -18,48 (-0,37 %)
     
  • Dow Jones

    37 986,40
    +211,02 (+0,56 %)
     
  • EUR/USD

    1,0661
    +0,0015 (+0,14 %)
     
  • Gold future

    2 406,70
    +8,70 (+0,36 %)
     
  • Bitcoin EUR

    60 213,03
    +2 215,22 (+3,82 %)
     
  • CMC Crypto 200

    1 371,97
    +59,34 (+4,52 %)
     
  • Pétrole WTI

    83,24
    +0,51 (+0,62 %)
     
  • DAX

    17 737,36
    -100,04 (-0,56 %)
     
  • FTSE 100

    7 895,85
    +18,80 (+0,24 %)
     
  • Nasdaq

    15 282,01
    -319,49 (-2,05 %)
     
  • S&P 500

    4 967,23
    -43,89 (-0,88 %)
     
  • Nikkei 225

    37 068,35
    -1 011,35 (-2,66 %)
     
  • HANG SENG

    16 224,14
    -161,73 (-0,99 %)
     
  • GBP/USD

    1,2370
    -0,0068 (-0,55 %)
     

The North America kidney disease market is expected to reach US$ 42,462.1 million in 2027 from US$ 25,483.5 million in 2019. The market is estimated to grow with a CAGR of 6.7% from 2020-2027

Market Introduction. Kidney disease is also known as renal disease. It is caused due to the malfunctioning of the kidney. There are various types of kidney diseases including kidney stones, glomerulonephritis, urinary tract infections, and others.

New York, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Kidney Disease Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; End User ; and Country" - https://www.reportlinker.com/p05999770/?utm_source=GNW
For the treatment and diagnosis of these types of diseases, different global and regional players are offering various products and services.

Market Overview and Dynamics
The North America kidney disease market is expected to reach US$ 42,462.1 million in 2027 from US$ 25,483.5 million in 2019. The market is estimated to grow with a CAGR of 6.7% from 2020-2027. The growth of the market is attributed to some key driving factors such as an increasing prevalence of chronic kidney related diseases and a high growth in aging population. However, the market is expected experiencing slow growth during the forecast period owing to failure in diagnosing cases of kidney diseases.

Key Market Segments
Based on product, the kidney disease market is segmented diagnosis and treatment.The diagnosis segment is further sub-segmented into blood tests, urine tests, imaging tests, and others.

The treatment segment is further sub-segmented into dialysis, drug class, and others.The drug class is sub-divided into ACE inhibitors, angiotensin-2 receptor blockers, diuretics, and others.

Based on end-user, the kidney disease market, is segmented into hospitals, diagnostic laboratories, and others.

Major Sources and Companies Listed
Some of the major primary and secondary sources for kidney disease market included in the report are American Urological Association, National Kidney Foundation, Kidney International Report, and others.

NORTH AMERICA KIDNEY DISEASE MARKET SEGMENTATION

By Product
• Diagnosis
o Blood Tests
o Urine Tests
o Imaging Tests
o Others
• Treatment
o Dialysis
o Others
o Drug Class
ACE Inhibitors
Angiotensin-II Receptor Blockers
Diuretics
Others

By End User
• Hospitals
• Diagnostic Laboratories
• Others
By Country
• North America
o US
o Canada
o Mexico

Company Profiles
• Abbott
• F. Hoffmann-La Roche Ltd
• AbbVie Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• GlaxoSmithKline plc.
• Amgen Inc.
• Sysmex Corporation
• Siemens AG
Read the full report: https://www.reportlinker.com/p05999770/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001